Drug Trial Radar · NCT02302456
Tranexamic Acid for Preventing Postpartum Haemorrhage Following a Vaginal Delivery
Last checked: Nov 19, 2026Latest source record: Sep 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,079
Actual
Start
Feb 2015
Primary completion
Jan 2017
Study completion Apr 2017
Sponsor
- Lead sponsor
- University Hospital, AngersGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Institut National de la Santé Et de la Recherche Médicale, France
- First posted
- Nov 27, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess whether the administration of a low dose of tranexamic acid just after vaginal delivery can reduce the incidence of immediate postpartum hemorrhage, in women who receive a prophylactic administration of oxytocin.
Conditions
- Immediate Postpartum Hemorrhage
Interventions
Tranexamic AcidDrug
Intravenous administration of a 10 mL solution containing 1g of tranexamic acid within 2 minutes of birth and routine prophylactic IV injection of oxytocin
PlaceboDrug
Intravenous administration of 10 mL of 0.9% sodium chloride solution within 2 minutes of birth and routine prophylactic IV injection of oxytocin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of PPHTime frame: 24 hours after birth
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Angers University Hospital
Angers, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.